74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Lonza Group AG
Open
SectorHealthcare
541.8 0.41
Overview
Share price change
24h
Min
539
Max
545
Income | 119M 426M |
|---|---|
Sales | 59M 3.6B |
P/E Sector Avg | 54.647 34.393 |
EPS | 4.31 |
Dividend yield | 0.7 |
Profit margin | 11.913 |
Employees | 19,299 |
EBITDA | 764M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +23.54% upside |
Dividend yield Sector Avg | 0.70% 2.54% |
|---|---|
Next Earnings | 23 Oct 2025 |
Market Cap | -3.2B 40B |
|---|---|
Previous open | 541.39 |
Previous close | 541.8 |
News Sentiment
By Acuity
15%
85%
19 / 374 Healthcare
Lonza Group AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Lonza Group AG Forecast
Price Target
By TipRanks
23.54% upside
12 Months Forecast
Average 668.6 CHF 23.54%
High 753 CHF
Low 603 CHF
Based on 10 Wall Street analysts offering 12 month price targets forLonza Group AG - Dist in the last 3 months.
Sentiment
By Acuity
19 / 374 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
